Roche Holding (ROG N) Stock Overview
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
ROG N Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Roche Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 8,138.86 |
| 52 Week High | CHF 8,260.79 |
| 52 Week Low | CHF 5,791.50 |
| Beta | 0.21 |
| 1 Month Change | 0.62% |
| 3 Month Change | 18.82% |
| 1 Year Change | 13.52% |
| 3 Year Change | 53.28% |
| 5 Year Change | 19.69% |
| Change since IPO | 131.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| ROG N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | -1.5% | -3.8% | -4.9% |
| 1Y | 13.5% | -0.1% | 23.1% |
Return vs Industry: ROG N exceeded the MX Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: ROG N underperformed the MX Market which returned 23.1% over the past year.
Price Volatility
| ROG N volatility | |
|---|---|
| ROG N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in MX Market | 5.9% |
| 10% least volatile stocks in MX Market | 2.8% |
Stable Share Price: ROG N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine ROG N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1896 | 103,249 | Thomas Schinecker | www.roche.com |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions.
Roche Holding AG Fundamentals Summary
| ROG N fundamental statistics | |
|---|---|
| Market cap | Mex$6.28t |
| Earnings (TTM) | Mex$296.86b |
| Revenue (TTM) | Mex$1.46t |
Is ROG N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROG N income statement (TTM) | |
|---|---|
| Revenue | CHF 63.36b |
| Cost of Revenue | CHF 16.16b |
| Gross Profit | CHF 47.19b |
| Other Expenses | CHF 34.31b |
| Earnings | CHF 12.88b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 16.19 |
| Gross Margin | 74.49% |
| Net Profit Margin | 20.33% |
| Debt/Equity Ratio | 83.5% |
How did ROG N perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 09:18 |
| End of Day Share Price | 2026/03/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Roche Holding AG is covered by 46 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Staszak | Argus Research Company |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Emily Field | Barclays |